Analysts Anticipate Medicenna Therapeutics Corp. (NYSE:MDNA) to Post -$0.04 EPS

Brokerages expect Medicenna Therapeutics Corp. (NYSE:MDNA) to announce ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Medicenna Therapeutics’ earnings. Medicenna Therapeutics reported earnings per share of ($0.05) in the same quarter last year, which suggests a positive year over year growth rate of 20%. The company is expected to report its next quarterly earnings report on Tuesday, November 3rd.

Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Medicenna Therapeutics.

Medicenna Therapeutics (NYSE:MDNA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.04) EPS for the quarter.

MDNA has been the topic of several analyst reports. Brookline Capital Management reaffirmed a “buy” rating on shares of Medicenna Therapeutics in a research note on Monday, August 24th. Bloom Burton reaffirmed a “buy” rating on shares of Medicenna Therapeutics in a research note on Monday, August 24th. Finally, HC Wainwright initiated coverage on shares of Medicenna Therapeutics in a research note on Thursday, September 10th. They set a “buy” rating and a $8.00 price target on the stock.

NYSE MDNA traded down $0.25 during trading hours on Tuesday, reaching $3.70. The company’s stock had a trading volume of 187,416 shares, compared to its average volume of 69,045. Medicenna Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $5.32. The business’s 50-day moving average price is $4.04.

About Medicenna Therapeutics

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.

Further Reading: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Medicenna Therapeutics (MDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.